Natco Pharma gains on USFDA nod for generic Bendamustine HCL powder

The stock moved higher by 6% to Rs 632 on the BSE in intra-day trade

Natco Pharma has moved higher by 6% to Rs 632 on the BSE in intra-day trade after the company said it has received final approval from US Food and Drug Administration (USFDA) for Bendamustine injection.

“The company has received final approval for abbreviated new drug application (ANDA) containing a paragraph IV certification filed with the USFDA for generic version of Bendamustine Hydrochloride powder for injection, 25 mg/vial and 100 mg/vial (Singe-Dose Vial),” Natco Pharma said in a press release.

The company plans to launch this drug on November 1, 2019, or earlier under certain circumstances, through its marketing